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Psychiatric Morbidity in Liver Transplant Patients 
A. DiMartini, K. Pajer, P. Trzepacz, J. Fung, T. Starzl, and R. Tringali 
q~b psyc,hiatric care of patients with organ transplants 
IS a rapidly groWIng area. Morbidity and mortality of 
transplantation are directly related to a number of factors 
including organ rejection and adverse complications of 
~edicationsK FK 506, a promising new immunosuppres-
sive drug, appears to significantly reduce the rate of 
rejection. During our center's several years of experience 
using FK 506, its side effect profile is being clarified. 
However. the psycqiatric morbidity associated with FK 
506 and the more traditionally used cyclosporine (CyA) 
has not been compared in any systematized fashion. 
Cognitive and psychiatric symptoms (eg, delirium. depres-
sion. insomnia. perceptual disturbances) may be important 
factors in the eventual outcome of these patients in that 
these symptoms may significantly impair their ability to 
comply with treatment regimens and interfere with their 
recovery. 
METHODS 
We participated in a randomized. nonblinded. controlled trial of 
FK 506 vs eyA in liver transplant patients. Exclusion criteria 
included previous/multiple transplants. hepatitis B or human 
immunovirus (HIV) carrier. cancer. renal failure. active infection. 
and coma. The outcomes of interest were cognitive function as 
assessed by the Mini-Mental State Exam (MMS) (Fig I), Trail-
making Tests (Trails) A and B. the Delirium Rating Scale (DRS). 
and a clinician-rated neuropsychiatric symptom checklist. Pa-
tients were initially assessed at 1 week postoperatively. a time 
when they had fully recovered from the effects of anesthesia. were 
mostly out of the intensive care unit. and had stabilized FK 506 or 
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eyA plasma levels. Pilot data for the first postoperative week are 
reported here (n = 24). 
RESULTS 
Demographic characteristics include age (mean = 40 ± 9, 
range 22 to 57), gender (46% female), and education (29% 
college educated). The primary liver diagnosis was alco-
holic cirrhosis in 42%, cryptogenic in 20%, primary biliary 
cirrhosis in 17%. and 20% other. There were no differences 
between the FK 506 group (n = 14) and CyA group (n = 
10) regarding age, gender, education. and liver diagnosis. 
MMS. Trails A and B. and DRS scores revealed that 
approximately 35% of the total group was experiencing 
some cognitive impairment. The symptom checklist re-
vealed that 51 % had more than four psychiatric symptoms 
(Fig 2), There was no statistical difference between FK 506 
and Cy A with respect to numbers of psychiatric symptoms 
(FK S06 = 4 :t 3, CyA = 5 :t 2) or DRS scores (FK 506 = 
7 :t 6, Cy A = 5 ± 2). MMS scores also were not 
significantly different (FK 506 = 26 ± 5, CyA = 28 ± 2), 
though more FK 506 patients had lower cognitive scores 
(21% less than 24 points) compared with none with CyA. 
The Trails tests are particularly sensitive to subtle disrup-
tions of sustained attention. visual-motor coordination, 
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Fig 2. Psychiatric symptoms. 
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Fig 3. FK 506 serum level versus Trails B. 
and symbol mediation. As we expected. plasma levels of 
both FK 506 and CyA were correlated with Trail B scores 
(r = .60. P = .03). suggesting that performances deterio-
rated with increasing drug levels (Fig 3). 
DISCUSSION 
Initial toxicologic studies in primates showed quietness. 
huddling postures. vomiting. anorexia. and weight loss at 3 
to 36 mglkg dose range of FK 506. with drowsiness and 
lethargy at the highest dosing range of 18 to 36 mglkg. I In 
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humans. the most common symptoms previously reponed 
include headache. nausea. vomiting. hyperesthesia. and 
flushing. which occurred with the greatest frequency dur-
ing IV administration.: These previous findings and our 
data suggest that higher plasma levels of FK 506 result in 
cognitive impairment and the development of untoward 
side effects. Anecdotally. we have suspected FK 506 in the 
development of delirium especially when plasma levels are 
high (ie. >4 to 5 ngldL). 
CONCLUSIONS 
Funher clinical experience with FK 506 has shown that 
lower plasma levels than those initially felt to be effective 
can be maintained without organ rejection. Perhaps by 
working to achieve the lowest possible dose to provide 
immunosuppression without rejection we will see fewer of 
the cognitive and neuropsychiatric symptoms experienced 
at higher plasma levels. Though our numbers are small. the 
current data suggest no statistically significant differences 
between FK 506 and Cy A with respect to gross cognitive 
functions and the development of neuropsychiatric symp-
toms. 
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